2:08 PM
 | 
Dec 01, 2017
 |  BC Week In Review  |  Company News  |  Deals

Acorda cashes out on Ampyra royalties

Acorda Therapeutics Inc. (NASDAQ:ACOR) granted HealthCare Royalty Partners (Stamford, Conn.) rights to royalty revenue for Ampyra dalfampridine (BIIB041), up to an undisclosed threshold, for $40 million. Acorda gained...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >